Eton Pharmaceuticals (NASDAQ:ETON) Earns Buy Rating from HC Wainwright

Eton Pharmaceuticals (NASDAQ:ETON)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $33.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 123.27% from the company’s current price.

A number of other equities analysts have also commented on ETON. Craig Hallum boosted their price target on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. B. Riley started coverage on shares of Eton Pharmaceuticals in a research report on Friday, January 10th. They issued a “buy” rating and a $21.00 price target on the stock.

Eton Pharmaceuticals Stock Down 0.7 %

NASDAQ ETON opened at $14.78 on Wednesday. The stock has a market cap of $385.03 million, a P/E ratio of -67.18 and a beta of 1.37. The company’s 50-day simple moving average is $15.56 and its 200 day simple moving average is $11.47. Eton Pharmaceuticals has a twelve month low of $3.03 and a twelve month high of $18.41.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.02). The business had revenue of $11.65 million for the quarter, compared to analysts’ expectations of $10.53 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. Research analysts anticipate that Eton Pharmaceuticals will post -0.14 earnings per share for the current year.

Hedge Funds Weigh In On Eton Pharmaceuticals

A number of large investors have recently modified their holdings of ETON. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Eton Pharmaceuticals by 86.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after purchasing an additional 30,167 shares in the last quarter. Wasatch Advisors LP acquired a new position in shares of Eton Pharmaceuticals during the third quarter worth approximately $1,431,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Eton Pharmaceuticals during the third quarter worth approximately $54,000. Parkman Healthcare Partners LLC lifted its position in shares of Eton Pharmaceuticals by 2.8% during the third quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock worth $1,561,000 after purchasing an additional 7,029 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Eton Pharmaceuticals during the third quarter worth approximately $90,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.